Clonal Hematopoiesis in Chronic Thromboembolic Pulmonary Hypertension Authors: Mizuki Momoi, Yoshinori Katsumata, Hiroyoshi Kunimoto, Takumi Inami, Fuyuki Miya, Atsushi Anzai, Shinichi Goto, Ayaka Miura, Yoshiki Shinya, Takahiro Hiraide, Kohsuke Shirakawa, Jin Endo, Keiichi Fukuda, Masaki Ieda, Kenjiro Kosaki, Hideaki Nakajima, Masaharu Kataoka Published: 2024 ABSTRACT AbstractBackgroundThe cause of chronic thromboembolic pulmonary hypertension (CTEPH) remains largely unknown. Recently, clonal hematopoiesis (CH) has been reported to be associated with cardiovascular and thromboembolic diseases. Here, we investigated the prevalence and clinical impact of CH in patients with CTEPH.Methods and ResultsWhole‐exome sequencing and deep‐panel sequencing were performed in 214 patients with CTEPH. Clinical data before and after treatment were compared between patients with and without CH. RNA sequencing and serum analysis were performed to explore the pathogenesis that CH contributes to CTEPH. Among the enrolled patients, 20.1%, notably 44.4% who were 80 to 89 years old, had variants in CH‐associated genes. In regard to clinical impact, B‐type natriuretic peptide levels and home oxygen therapy rate were significantly higher, and 6‐minute walk distance was significantly shorter after treatment in patients with CH than in those without CH. Moreover, novel clot reformation in the pulmonary artery despite the use of anticoagulants and additional angioplasty events after treatment completion were more frequent in patients with CH. RNA sequencing analysis revealed that blood coagulation and neutrophil extracellular trap formation pathways were enriched in patients with CH. Additionally, serum citrullinated histone H3 levels were higher in patients with CH than those without CH. These results were consistent in the subgroup of patients who did not have the history of hematological disorders.ConclusionsThe findings in this study raise the possibility that CH will induce a more prothrombotic state through neutrophil activation and neutrophil extracellular trap formation, contributing to pathogenesis and poor treatment response in patients with CTEPH.Keywords: balloon pulmonary angioplasty, chronic thromboembolic pulmonary hypertension, clonal hematopoiesis, clot formation, neutrophil extracellular trapSubject Categories: Genetics, Precision Medicine, Pulmonary Hypertension, Translational Studies, Vascular Disease Nonstandard Abbreviations and Acronyms 6‐minute walk distance balloon pulmonary angioplasty clonal hematopoiesis chronic thromboembolic pulmonary hypertension essential thrombocythemia home oxygen therapy neutrophil extracellular trap pulmonary arterial pressure pulmonary endarterectomy pulmonary hypertension right heart catheterization variant allele frequency whole‐exome sequencing Clinical Perspective What Is New? The findings in this study raise the possibility that clonal hematopoiesis induces a more prothrombotic state through neutrophil activation and neutrophil extracellular trap formation, contributing to pathogenesis and poor treatment response in patients with chronic thromboembolic pulmonary hypertension. The findings in this study raise the possibility that clonal hematopoiesis induces a more prothrombotic state through neutrophil activation and neutrophil extracellular trap formation, contributing to pathogenesis and poor treatment response in patients with chronic thromboembolic pulmonary hypertension. What Are the Clinical Implications? Patients with chronic thromboembolic pulmonary hypertension who had variants in clonal hematopoiesis‐associated genes should be carefully followed up because of poor treatment response and higher rate of thrombus reformation in the pulmonary artery despite the use of anticoagulants. Patients with chronic thromboembolic pulmonary hypertension who had variants in clonal hematopoiesis‐associated genes should be carefully followed up because of poor treatment response and higher rate of thrombus reformation in the pulmonary artery despite the use of anticoagulants. Precision medicine based on genetic analysis may also be considered in chronic thromboembolic pulmonary hypertension. Precision medicine based on genetic analysis may also be considered in chronic thromboembolic pulmonary hypertension. Chronic thromboembolic pulmonary disease is a disease defined by persistent chronic pulmonary vascular obstruction by thromboemboli. According to the recent European guideline, patients who do not meet the pulmonary hypertension (PH) criteria are referred to as having chronic thromboembolic pulmonary disease without PH, whereas those who do are described as having chronic thromboembolic pulmonary disease with PH, specifically known as chronic thromboembolic pulmonary hypertension (CTEPH). 1 Although various risk factors for CTEPH, such as a history of cancer, chronic inflammatory diseases, and antiphospholipid antibody syndrome, have been recognized, 2 many patients with CTEPH do not have these factors or prothrombotic dispositions. 3 Additionally, although effective treatments for CTEPH, such as pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA), and pulmonary vasodilators, have been developed, 4 , 5 some patients present poor treatment responses. The recurrence of venous thrombosis events has been reported in some patients after PEA or BPA, irrespective of anticoagulation therapy. 6 , 7 , 8 Therefore, it is suggested that an unknown thrombogenic predisposition or mechanism is involved in the development and treatment response of CTEPH. Clonal hematopoiesis (CH) is the state in which driver variants occur in hematopoietic stem cells, resulting in the production of a substantial proportion of circulating blood cells from a single mutated stem cell. 9 Recently, the importance of CH has been frequently reported in hematological and cardiovascular diseases. 10 Interestingly, CH has been clarified as a risk of coronary artery disease, heart failure, cardiomyopathy, and pulmonary arterial hypertension and as an independent poor prognostic predictor in the general cohort. 11 , 12 , 13 , 14 , 15 In addition to cardiovascular diseases, recent studies have demonstrated that CH also has a higher prevalence of venous thromboembolic diseases. 16 , 17 Moreover, CH increases in frequency with age in the general population, 9 and CTEPH has a higher incidence in older people. 2 Consequently, these results support the hypothesis that CH could be involved in the pathogenesis of CTEPH. Therefore, we focused on the role of CH in patients with CTEPH and performed a multicenter analysis to investigate the prevalence of CH and evaluate its involvement in the pathogenesis and clinical significance of CTEPH. Methods The data that support the findings of this study are available from the corresponding author upon reasonable request if ethical requirements for data sharing can be fulfilled. Study Cohort This study was performed at Keio University Hospital and Kyorin University Hospital in Japan and was approved by the institutional ethics committee of both universities (approval number: 20140203 and 20170213 in Keio University, H26‐125 in Kyorin University). Additionally, this study protocol complies with the guidelines of the Declaration of Helsinki, and written informed consent was obtained from all patients. Patients with CTEPH who were referred to Keio University Hospital or Kyorin University Hospital from 2010 to 2021 were included. The CTEPH diagnosis was made according to the current guideline, 18 and right heart catheterization (RHC) was performed by dedicated cardiologists without sedation. In this study, the chronic thrombi in the pulmonary arteries were confirmed using pulmonary angiography, and the hemodynamics of CTEPH were defined as mean pulmonary arterial pressure (PAP) >25 mm Hg and pulmonary artery wedge pressure <15 mm Hg using RHC at rest after at least 3 months of anticoagulation therapy. The operability of patients with CTEPH was discussed by institutional cardiologists and cardiovascular surgeons who were experts in PEA, according to the current guideline. 18 Inoperable patients with CTEPH were considered appropriate candidates for BPA. In patients who could not undergo invasive treatment (PEA or BPA) for individual reasons, only medication therapy, including anticoagulants and/or pulmonary vasodilators, was used. Whole‐Exome Sequencing and Panel Sequencing to Identify CH‐Associated Genes All patients received genetic counseling, and all genetic tests were performed with informed consent. DNA was extracted from peripheral white blood cells. The genetic tests in this study included whole‐exome sequencing (WES) and deep sequencing using panel sequencing specialized for detecting CH. The detailed methods of WES are described in our previous reports. 19 Briefly, DNA was sequenced using a HiSeq 2500 platform (Illumina, San Diego, CA) and a SureSelectXT Human All Exon Kit (Agilent Technologies, Santa Clara, CA) for hybridization capture. Reads were mapped to the reference genome (GRCh37) using Burrows‐Wheeler Aligner (version 2.10.12), and somatic variants were called using MuTect2 (version 4.1.4.1). WES data were also processed using the somatic pipeline of Illumina DRAGEN Enrichment version 4.0.3 for validation with default settings. The panel sequencing was also performed with the same DNA collected from peripheral white blood cells. AmpliSeq for Illumina Myeloid Panel (Illumina) was applied for the deep sequencing. The library preparation was performed according to the product guide. The DNA was sequenced using the NovaSeq6000 sequencing system (Illumina). Finally, the variants were called using the somatic pipeline of Illumina DNA amplicon version 2.1.1 with default settings, and samples with a mean coverage depth of <×500 were excluded because of low quality. To compare the frequency of CH in patients with CTEPH among the Japanese population, CH in patients with cardiomyopathy who were referred to Keio University Hospital were also analyzed using WES in the same methods described above. Variant Calling CH‐associated variants were defined as pathogenic somatic variants associated with human hematologic cancers using the variant lists in the previous CH analyses by Bick et al. 20 The lists of CH‐associated genes adopted in this study are presented in Table S1. The cutoff value of variant allele frequency (VAF) was set to 0.02, and variants with a VAF of 0.4 to 0.6 were excluded because the possibility of germline variants could not be ruled out. Variants whose minor allele frequency was >0.01 in the general cohort were also excluded because of the low pathogenicity. Furthermore, the minimum variant allele depth was set to be ×3. In cases where the same variants were detected using WES and panel sequencing, VAF from panel sequencing was used because of the high depth. Moreover, the splicing variants were defined as within 2 base pairs from splicing sites. Clinical Parameters and Outcomes All clinical data were obtained by collaborators who were blinded to the study groups. The data at diagnosis, including medical history, home oxygen therapy (HOT) usage, World Health Organization functional class, blood tests, medications, 6‐minute walk distance (6MWD), hemodynamics measured using RHC, and surgical classification using pulmonary angiography 21 were collected. Cardiac output and pulmonary vascular resistance were calculated using the Fick method. In addition to the timing of diagnosis, the follow‐up data, including HOT usage, World Health Organization functional class, blood tests, 6MWD, and hemodynamics measured using RHC, were collected at the timing of follow‐up RHC at 1 year after the completion of invasive treatment (PEA or BPA) or diagnosis in cases without invasive treatment. In cases where there were no 1‐year follow‐ups, we adapted nearest timing of follow‐up from 1 year after treatment completion. The clinical parameters were compared between patients with CH and those without CH at both times. An additional BPA event was defined as a repeated BPA attempt at least 1 year after the completion of PEA or BPA due to a re‐elevation of the mean PAP or worsening of the patient's symptoms related to CTEPH. The novel thrombus events were defined as newly detected clots that were not found at diagnosis in the pulmonary artery despite the continued use of anticoagulants. The events were counted if new thrombus was detected using either or both computed tomography scan or pulmonary angiography. Computed tomography images were assessed by independent radiologists, and the pulmonary artery angiogram was evaluated by independent operators who were blind to the presence of CH. Time in therapeutic range (international normalized ratios between 1.5 and 3.0) for warfarin was compared between patients who were CH‐positive and patients who were CH‐negative, and the Kaplan‐Meier event‐free analysis for the novel thrombus events in pulmonary arteries was performed. A Cox proportional hazards model was used as a multivariate time versus event analysis. HLA Typing The human leukocyte antigen (HLA) typing was performed from WES data using HLA typing from high‐quality dictionary (HLA‐HD; version 1.7.0) application. 22 The presence of HLA‐B*5201 and HLA‐DPB1*0202 were confirmed in all the patients. RNA Sequencing RNA was also extracted from peripheral white blood cells at the same time as DNA extraction. Poly(A) RNA and library preparation were performed using the NEBNext UltraII Directional RNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA). RNA was sequenced at least 6 Gb per sample with NovaSeq 6000 (Illumina). Adapter sequences and low‐quality bases were trimmed using Trimmomatic software (version 0.38). The sequence reads also underwent a quality check with FastQC (version 0.11.7). Next, the trimmed reads were mapped using STAR (version 2.7.0a), and the transcriptional level per gene was quantified with RSEM (version 1.3.3). Therefore, to detect differentially expressed genes, the raw count data were analyzed using DESeq2 (version 3.16). A false discovery rate of <0.1 and folding change of ≥1.5 were set as the cutoff values of differentially expressed genes. The volcano plot was made using GraphPad Prism (version 8.0 for Mac; GraphPad Software, La Jolla, CA). Differentially expressed genes were uploaded to the Metascape platform (http://metascape.org) for enrichment analysis. 23 The Kyoto Encyclopedia of Genes and Genomes pathway analysis was performed by the generally applicable gene‐set enrichment method using integrated differential expression and pathway analysis. 24 Quantification of Citrullinated Histone H3 and Cell‐Free DNA First, the patient's sera were extracted from peripheral blood at the same time as DNA extraction. Next, the samples were rapidly divided into aliquots and stored at –80 °C. The citrullinated histone H3 and cell‐free DNA levels were measured using the citrullinated histone H3 (clone 11D3) ELISA Kit (Cayman) and Quant‐iT PicoGreen dsDNA Assay Kit (Invitrogen, Thermo Fisher Scientific), respectively, according to the manufacturer's guides. Finally, the fluorescence and absorbance were measured using the Cytation 5 Cell Imaging Multi‐Mode Reader (BioTek), and all studies were conducted in duplicate. Quantification of Plasma Cytokines The patient's plasma was extracted from peripheral blood at the same time as DNA extraction, and the samples were stored at –80 °C. The cytokine levels were measured using Human XL Cytokine Luminex Performance Assay 46‐Plex Fixed Panel (R&D Systems), according to the manufacturer's guides. The beads were counted using the LabScan 100 (Thermo Fisher Scientific). Patients with active cancer and autoimmune disease were excluded from analysis. Patients with remaining specimens were selected by matching age and sex propensity using the MatchIt package in R software. Subgroup Analysis In this study, the subgroup analyses in the cohort of patients without hematological disorders were performed. Patients’ baseline characteristics, treatment response, RNA sequencing analysis, citrullinated histone H3, and cell‐free DNA were compared between patients with and without CH. Statistical Analysis Continuous data are described as median with interquartile range (IQR) or mean±SEM, as appropriate, whereas categorical data are expressed as number and percentage. Mann‐Whitney U test or Student t test and χ2 or Fisher exact tests were used for continuous and categorical data, respectively, as appropriate, to evaluate the differences in the clinical data and the sample data between patients with CH and those without CH. The Wilcoxon signed rank test was used to compare baseline and posttreatment continuous variable data. In particular, to compare the treatment response in patients with and without CH, clinical parameters at follow‐up were compared. At the same time, each clinical parameter was compared at baseline and follow‐up in both of the groups. These calculated P values were adjusted by the Holm method as a multiple‐testing correction. A 2‐way repeated measures analysis of variance was also used to assess the differences in the changes from baseline to follow‐up between patients with and without CH. Statistical significance was considered at P<0.05. As a multivariate analysis, the logistic regression analysis and the multivariable linear regression analysis were used for binominal and continuous variables, respectively. All P values were 2‐tailed. Furthermore, to calculate the allele frequency in the general population, the data from gnomAD (https://gnomad.broadinstitute.org) and ToMMo (https://jmorp.megabank.tohoku.ac.jp) were used in this study. Statistical analyses were performed using SPSS statistical software package (version 27.0; IBM, Armonk, NY) and R software (version 3.6.3). Figures were made using GraphPad Prism (version 8.0 for Mac; GraphPad Software) and R software (version 3.6.3). Results Patients’ Cohort and Clinical Characteristics Overall, 219 patients with CTEPH were enrolled in this study, and WES and panel sequencing were performed. Of these, 5 patients were excluded because of the panel sequencing quality. Therefore, 214 patients with CTEPH were analyzed. The Table summarizes the patients’ characteristics and hemodynamics. Additionally, the patients were predominantly women (72.9%) with a median age of 63 (IQR, 54–72) years at diagnosis. Approximately half of the patients had a history of pulmonary embolism or deep venous thrombosis. The mean PAP, cardiac output, and pulmonary vascular resistance were 39 (IQR, 32–46) mm Hg, 3.70 (IQR, 2.95–4.36) L/min, and 8.4 (IQR, 5.9–12.9) Wood units, respectively. The frequencies of surgical classification levels I, II, III, and IV were 0.5%, 28.3%, 40.6%, and 30.7%, respectively. Furthermore, approximately two‐thirds of the patients received HOT. The functional test on coagulation could not be assessed, because anticoagulant drugs including warfarin or direct oral anticoagulants had been already used at baseline. Table S2 summarizes the treatment strategy and medication data. Among the patients, 17.8% and 83.6% underwent PEA and BPA, respectively. Identification of Variants in CH‐Associated Genes WES and panel sequencing were performed to investigate the prevalence of variants in CH‐associated genes according to the CH criteria used in the latest CH study by Bick et al. 20 Overall, 43 (20.1%) of the 214 patients with CTEPH had variants in CH‐associated genes, and the total number of these variants was 59 (Table S3). In regard to variants with VAF >20%, a total of 13 variants were found in 13 patients who were CH‐positive. Among these 13 patients, 4 had hematological diseases, of whom 3 had essential thrombocythemia (ET) and 1 had myelodysplastic syndrome. The 3 patients with ET were treated with only hydroxycarbamide, and the 1 with myelodysplastic syndrome did not receive chemotherapy. Details and VAF for all variants identified in patients with CTEPH are presented in Table S4. Furthermore, CH frequency was also analyzed by age (Figure 1), and it was 25.4% and 44.4% in patients with CTEPH 70 to 79 years old and 80 to 89 years old, respectively. Prevalence of CH in patients with CTEPH. The frequency of CH in patients with CTEPH detected using WES and deep panel sequencing is shown by age. The details on the analysis based on the previous reports and explored variants are described in Tables S1, S4. The error bars represent 95% CIs. CH indicates clonal hematopoiesis; CTEPH, chronic thromboembolic pulmonary hypertension; and WES, whole‐exome sequencing. Comparison of CH Frequency With Patients With Cardiomyopathy CH frequency in 190 Japanese patients with cardiomyopathy was analyzed using WES alone for comparison. Patients with cardiomyopathy were predominantly men (74.7%) with a median age of 65 (IQR, 55–75) years. Among them, 52.6%, 29.5%, 14.7%, 2.1%, and 1.1% of patients were diagnosed with dilated cardiomyopathy, cardiac amyloidosis, hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy, and cardiac sarcoidosis, respectively. A total of 24 variants in CH‐associated genes were detected in 18 patients who were CH‐positive with cardiomyopathy (Table S5), and CH frequency tended to be higher in patients with CTEPH than in patients with cardiomyopathy ≥50 years old (Figure S1). Characteristics of the Identified Variants Figure 2 and Figure S2 summarize the features of the variants identified using WES and panel sequencing in patients with CTEPH according to the CH criteria used in the recent CH study by Bick et al. 20 The gene where variants were most frequently identified was DNMT3A, followed by TET2, JAK2, and ASXL1 (Figure 2A). Among 43 patients with CH, 11 (26%) had 2 or more variants in the CH‐associated genes (Figure 2B), and 1 had up to 4 variants. In regard to the types of variants, just half (50%) of the variants were truncated, indicating nonsense and frameshift variants, and splice site variants were observed in 3.3% of all variants (Figure 2C). Furthermore, when the accumulated variants were counted, the JAK2 V617F variant, which was by far the most frequent variant in this cohort, was confirmed in 8 patients, in whom 3 had been diagnosed as ET and 1 had myelodysplastic syndrome (Figure 2D). Moreover, the VAF of 23 variants was >10% (Figure 2E), whereas the most frequent variant identified with >10% of VAF was JAK2, followed by DNMT3A, ASXL1, and PPM1D (Figure 2F). Analysis of variants identified in CH‐associated genes. A, The number of variants identified in each of the CH‐associated genes is listed in order of frequency. B, The number of patients based on the number of variants identified per patient is shown in order of frequency. C, The distribution of types of variants is summarized. D, The number of accumulated variants identified in patients with CTEPH is displayed in order of frequency. E, The number of variants based on VAF is summarized. F, The number of variants with VAF of >10% in each CH‐associated gene is listed in order of frequency. ASXL1 indicates additional sex combs like 1; CH, clonal hematopoiesis; CTEPH, chronic thromboembolic pulmonary hypertension; DNMT3A, DNA methyltransferase 3A; GNAS, guanine nucleotide binding protein, α stimulating; JAK2, Janus kinase 2; PHIP, pleckstrin homology domain interacting protein; PPM1D, protein phosphatase, Mg2+/Mn2+ dependent 1D; SF3B1, splicing factor 3b subunit 1; SRSF2, serine and arginine rich splicing factor 2; TET2, tet methylcytosine dioxygenase 2; TP53, tumor protein p53; VAF, variant allele frequency; and ZRSR2, zinc finger CCCH‐type, RNA binding motif and serine/arginine rich 2. Association Between CH and Baseline Clinical Characteristics To assess the clinical significance of having CH in patients with CTEPH, the baseline clinical characteristics were compared between patients with CH (CH‐positive group) and those without (CH‐negative group; Table). Their age was significantly older, and more women existed in the CH‐positive group. Among 214 patients, 8 had hematological disorders, including 3 patients with ET. All 3 patients with ET had the JAK2 V617F variant and thrombocytosis, and 1 of them also had leukocytosis. However, all 3 patients did not present other clinical features of ET, and CTEPH was the only thromboembolic event. They were receiving medication therapy with hydroxycarbamide. The laboratory data, including B‐type natriuretic peptide (BNP), hemodynamics, HOT usage rate, and 6MWD, were not significantly different between the patients with and without CH. Additionally, the hemodynamic parameters, such as mean PAP, cardiac output, and pulmonary vascular resistance, were not significantly different between the groups. The CH‐positive group tended to have a more proximal distribution of organized thrombi scored using surgical classification but without statistical significance. Furthermore, the treatment strategy was also investigated, and the rate of PEA, BPA, or only medication therapy did not statistically differ between the groups (Table S2). Approximately 80% of patients in both groups underwent BPA in this study. Moreover, the types of medication therapy, including anticoagulants and pulmonary vasodilators, were not statistically different between the groups (Table S2). Table 1Baseline Characteristics of Patients With CTEPHVariablesAll (n=214)Missing values, nCH− (n=171)Missing values, nCH+ (n=43)Missing values, n P valueWomen, n (%)156 (72.9%)—119 (69.6%)—37 (86.0%)—0.048Age at diagnosis, y63 (IQR, 54–72)—61 (IQR, 52–70)—71 (IQR, 67–77)—<0.001Blood group non‐O175 (82.5%)2141 (82.9%)134 (81.0%)10.76HLA‐B*520169 (32.2%)—55 (32.2%)—14 (32.6%)—0.96HLA‐DPB1*020212 (5.6%)—9 (5.3%)—3 (7.0%)—0.66History of DVT/PE, n (%)106 (49.5%)—87 (50.9%)—19 (44.2%)—0.54History of IHD, n (%)14 (6.5%)—11 (6.4%)—3 (7.0%)—1.0History of malignancy, n (%)25 (11.7%)—15 (8.8%)—10 (23.3%)0.008History of systemic lupus erythematosus, n (%)2 (0.9%)—2 (1.2%)—0 (0%)—0.48History of hematological disorders, n (%)8 (3.7%)—3 (1.8%)—5 (11.6%)—0.009Essential thrombocythemia, n (%)3 (1.4%)—0 (0%)—3 (7.0%)—0.008Myelodysplastic syndrome, n (%)2 (0.9%)—1 (0.6%)—1 (2.3%)—0.36Malignant lymphoma, n (%)2 (0.9%)—1 (0.6%)—1 (2.3%)—0.36Acute promyelocytic leukemia, n (%)1 (0.5%)—1 (0.6%)—0 (0%)—1.0History of smoking, n (%)49 (22.9%)—42 (24.6%)—7 (16.3%)—0.34WBC, 102/L61 (IQR, 51–72)960 (IQR, 51–71)762 (IQR, 53–72)20.33RBC, 104/L450 (IQR, 406–490)9452 (IQR, 409–491)7442 (IQR, 392–487)20.77Hemoglobin, g/dL13.6 (IQR, 12.3–15.0)913.8 (IQR, 12.4–15.1)713.3 (IQR, 12.1–14.4)20.20Platelets, 104/L23.8 (IQR, 19.1–28.5)923.6 (IQR, 19.1–28.2)724.5 (IQR, 20.2–29.5)20.18eGFR, mL/min per 1.73 m2 61 (IQR, 47–73)961 (IQR, 48–73)756 (IQR, 47–71)20.50BNP, pg/mL76 (IQR, 30–255)778 (IQR, 28–233)573 (IQR, 34–323)20.71Antiphospholipid antibody, n (%)12 (5.6%)—10 (5.8%)—2 (4.7%)—0.76WHO‐FC of I/II/III/IV, n (%)4/44/142/7174/38/110/6130/6/32/140.42(2.0%/22.3%/72.1%/3.6%)(2.5%/24.1%/69.6%/3.8%)(0%/15.4%/82.1%/2.6%)HemodynamicsMean RAP, mm Hg5 (IQR, 2–7)85 (IQR, 3–7)65 (IQR, 2–7)20.53Mean PAP, mm Hg39 (IQR, 32–46)240 (IQR, 32–46)136 (IQR, 32–46)10.33PAWP, mm Hg8 (IQR, 6–10)88 (IQR, 6–10)68 (IQR, 6–10)20.65CO, L/min3.70 (IQR, 2.95–4.36)83.70 (IQR, 2.95–4.40)63.48 (IQR, 2.95–4.30)20.44PVR, Wood units8.4 (IQR, 5.9–12.9)88.5 (IQR, 5.9–13.3)67.9 (IQR, 6.0–11.1)20.56Surgical classification of I/II/III/IV,* n (%)1/60/86/6521/46/66/5620/14/20/900.430.5%/28.3%/40.6%/30.7%)(0.6%/27.2%/39.1%/33.1%)(0%/32.6%/46.5%/20.9%)HOT usage, n (%)136 (67.3%)12104 (64.2%)932 (80.0%)30.0856MWD, m370 (IQR, 269–420)35371 (IQR, 273–427)29365 (IQR, 250–400)60.15Data are expressed as number (%) or median (IQR). The number of missing values due to the absence of medical records is presented. P values from a 2‐sided Mann‐Whitney U test for continuous data and 2‐sided χ2 or Fisher exact test for categorical data, as appropriate, are shown. 6MWD indicates 6‐minute walk distance; BNP, B‐type natriuretic peptide; CH, clonal hematopoiesis; CO, cardiac output; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen; HOT, home oxygen therapy; IHD, ischemic heart disease; IQR, interquartile range; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PE, pulmonary embolism; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RBC, red blood cell; WBC, white blood cell; and WHO‐FC, World Health Organization functional class.*Surgical classification levels of CTEPH were assessed according to the previous report. 21 Baseline Characteristics of Patients With CTEPH Data are expressed as number (%) or median (IQR). The number of missing values due to the absence of medical records is presented. P values from a 2‐sided Mann‐Whitney U test for continuous data and 2‐sided χ2 or Fisher exact test for categorical data, as appropriate, are shown. 6MWD indicates 6‐minute walk distance; BNP, B‐type natriuretic peptide; CH, clonal hematopoiesis; CO, cardiac output; CTEPH, chronic thromboembolic pulmonary hypertension; DVT, deep vein thrombosis; eGFR, estimated glomerular filtration rate; HLA, human leukocyte antigen; HOT, home oxygen therapy; IHD, ischemic heart disease; IQR, interquartile range; PAP, pulmonary arterial pressure; PAWP, pulmonary arterial wedge pressure; PE, pulmonary embolism; PVR, pulmonary vascular resistance; RAP, right atrial pressure; RBC, red blood cell; WBC, white blood cell; and WHO‐FC, World Health Organization functional class. Surgical classification levels of CTEPH were assessed according to the previous report. 21 Clinical Significance of CH in Treatment Response The patients’ hemodynamics, BNP, 6MWD, and World Health Organization functional class were evaluated during the follow‐up (Figure 3; Table S6). The median follow‐up period from diagnosis to follow‐up was 643 (IQR, 501–886) days. Additionally, the mean PAP, cardiac output, and pulmonary vascular resistance at follow‐up did not significantly differ between the groups; however, BNP levels and HOT usage rates at follow‐up were significantly higher in the CH‐positive group than in the CH‐negative group. Moreover, 6MWD at follow‐up was significantly shorter in the CH‐positive group than in the CH‐negative group. The multivariate analysis, which adjusted for age, sex, BNP levels at diagnosis, mean PAP at diagnosis, and follow‐up period, showed that CH was significantly associated with increased BNP levels and HOT usage rates at follow‐up (Tables S7–S9). Notably, additional BPA events were also significantly more frequent in the CH‐positive group than in the CH‐negative group. Furthermore, despite the continued use of anticoagulants after diagnosis, significantly more novel thrombus events in the pulmonary artery occurred in the CH‐positive group than in the CH‐negative group. Moreover, the Kaplan‐Meier event‐free analysis also demonstrated that the novel thrombotic events were significantly more frequent in CH‐positive group than in CH‐negative group (Figure 4). CH was also the risk of the event by Cox proportional hazards model adjusted for age and sex (Table S10). Time in therapeutic range in patients who were treated with warfarin did not statistically differ among those with and without CH (median time, 87.1% [IQR, 80.7%–97.2%] versus 89.4% (IQR, 77.5%–94.8%), respectively; P=0.75]. Therefore, these findings represent the relative refractoriness to treatment in the CH‐positive group. Changes in clinical parameters at baseline and after treatment. The hemodynamics, log10 BNP, and 6MWD measured at baseline and after treatment in patients with CH (CH+) and those without CH (CH–) are shown. The Mann‐Whitney U test was used for differences between patients with and without CH, and the Wilcoxon signed rank test was used for comparisons between baseline and posttreatment data. A 2‐way repeated measures analysis of variance was also used to assess the differences in the changes from baseline to follow‐up between patients with and without CH. Boxplot's box indicates the 25th and 75th percentile, with the center bar as the median value. 6MWD indicates 6‐minute walk distance; BNP, B‐type natriuretic peptide; CH, clonal hematopoiesis; CO, cardiac output; PAP, pulmonary arterial pressure; PVR, pulmonary vascular resistance; and RAP, right atrial pressure. Kaplan‐Meier event‐free analysis for the events of novel thrombus in the pulmonary artery. Kaplan‐Meier event‐free analysis demonstrated that the novel thrombotic events were significantly more frequent in the CH‐positive group than in the CH‐negative group. CH indicates clonal hematopoiesis. RNA Sequencing Analysis RNA from patients’ peripheral white blood cells was collected in 124 patients with CTEPH (27 and 97 patients from the CH‐positive and CH‐negative groups, respectively). RNA sequencing revealed that 342 genes were differentially upregulated in the CH‐positive group (Figure 5A). Enrichment analysis of upregulated differentially expressed genes showed that blood coagulation and platelet aggregation were enriched in the CH‐positive group (Figure 5B), which corresponds to more frequent novel thrombus events in the pulmonary artery identified in the CH‐positive group compared with the CH‐negative group. The neutrophil degranulation and inflammatory response were also enriched in the CH‐positive group (Figure 5B). The pathway analysis using the Kyoto Encyclopedia of Genes and Genomes showed that the neutrophil extracellular trap (NET) formation pathway was significantly enriched in the CH‐positive group (Figure 5C). RNA sequencing analysis and NET formation assay. The volcano plot (A), the enrichment analysis using the metascape (B), and the KEGG pathway analysis using the GAGE method (C) comparing patients with CH and those without CH. D, Levels of serum citrullinated histone H3 and cell‐free DNA, which are the common NET markers, in patients with CH and those without CH. Data are shown as the mean±SEM. CH indicates clonal hematopoiesis; FDR, false discovery rate; GAGE, generally applicable gene‐set enrichment; KEGG, Kyoto Encyclopedia of Genes and Genomes; and NET, neutrophil extracellular trap. Evaluation of NET Formation The citrullinated histone H3 levels and the cell‐free DNA in the patients’ sera, which are the common NET markers, were evaluated to confirm the RNA sequencing results on NET formation. Notably, the citrullinated histone H3 levels were significantly higher in the CH‐positive group than in the CH‐negative group, and cell‐free DNA levels tended to be higher in the CH‐positive group than in the CH‐negative group but without statistical significance (Figure 5D). Quantification of Plasma Cytokines A total of 46 types of plasma cytokines were measured in 23 and 53 patients in the CH‐positive and CH‐negative groups, respectively. The results of all cytokines were presented in Table S11. Although 9 cytokines were significantly lower in the CH‐positive group than in the CH‐negative group, most of the cytokines were not significantly different between the groups. Subgroup Analysis of Patients Without Hematological Disorders The subgroup analysis results of the cohort of patients without hematological disorders are presented in Tables S12, S13, and Figure S3. Among 206 patients without hematological disorders, 38 patients had CH and 168 did not. Patients with CH presented significantly higher BNP levels and lower 6MWD after treatment. Additional BPA events and novel thrombus formation in pulmonary arteries were significantly more frequent in patients with CH than patients without CH. RNA sequencing analysis (24 and 95 patients from the CH‐positive and CH‐negative groups, respectively) revealed that clot formation, inflammatory response, and neutrophil extracellular traps were significantly enriched in patients with CH, in addition to the higher citrullinated histone H3 levels. Discussion In this study, we demonstrated CH frequency in patients with CTEPH; notably, 20.1% had CH. It was also shown that patients with CH had higher BNP values, higher HOT usage rates, and shorter 6MWD after treatment than those without CH, in addition to the higher rate of novel thrombosis in the pulmonary artery and needed more additional BPA. RNA sequencing showed that the gene ontology of blood coagulation and the NET formation pathway were enriched in patients with CH and serum citrullinated histone H3 levels, which is one of the markers of NET formation, and were higher in patients with CH than in those without CH. These results were also confirmed in the subgroup analysis in patients without hematological disorders. Although the risk of CH for arterial diseases such as coronary heart disease is well recognized, 25 the analysis of the association between CH and venous thrombosis remains limited. A pilot study of 61 patients with unprovoked pulmonary embolism recently reported that 20% of them had CH. 16 More recently, a preliminary study showed that CH with VAF >10% was associated with a higher risk for venous thrombosis (hazard ratio [HR], 1.60) and pulmonary embolism (HR, 1.80). 17 These reports indicated that CH could be a risk factor for arterial vascular and venous thrombotic diseases. Moreover, in this study, the incidents of novel thrombi in the pulmonary artery, despite the continued use of anticoagulants, were statistically more frequent in patients with CH than in those without CH. Additionally, these patients tended to have a more proximal distribution of organized thrombi scored using surgical classification, 21 implicating a higher clot volume in patients with CH than in those without CH. Therefore, these findings support the idea that CH could induce a more prothrombotic state in CTEPH. RNA sequencing analysis in this study revealed that platelet aggregation and blood coagulation were significantly enriched in patients with CH. These results support the prothrombotic state of patients with CH, as estimated from clinical data. Interestingly, RNA sequencing also showed that neutrophil degranulation is at the top of the enriched gene ontology. Moreover, the Kyoto Encyclopedia of Genes and Genomes pathway analysis demonstrated that the NET formation pathway was significantly enriched in patients with CH. NET formation was originally discovered as the defense mechanism of neutrophils against various pathogens, such as viral and bacterial infections, 26 and the NET formation process is known as NETosis. Recently, this NET formation has been reported to be associated with thrombosis through various mechanisms. 27 , 28 , 29 Moreover, other studies showed that neutrophils and NETosis were found in the thrombi at the pulmonary artery in patients with CTEPH in addition to the elevated levels of serum NET markers, 30 , 31 which supports the idea that NET formation could be involved in CTEPH pathogenesis. In regard to the association of NETs with CH, the JAK2 V617F variant reportedly promotes NET formation, leading to a prothrombotic state. 32 Combined with these reports, this study provided a novel insight that patients with CTEPH who had CH were in a prothrombotic state possibly through CH‐induced NET formation (Figure 6). Although comprehensive analysis of plasma cytokines was performed to assess the inflammatory response and B‐cell signaling pathway, which were detected from our RNA sequencing data, most of the plasma cytokines were not significantly different between the patients who were CH‐positive and the patients who were CH‐negative. Moreover, the frequency of patients with systemic lupus erythematosus and antiphospholipid antibodies was not significantly different between the groups, although the systemic lupus erythematosus pathway was top elevated in Kyoto Encyclopedia of Genes and Genomes pathway analysis. From these data, the NET formation pathway was thought to be the most relevant pathway affected by CH in patients with CTEPH. Potential pathogenesis of CTEPH medicated with CH. The findings in this study suggest that CH induces a more prothrombotic state possibly through neutrophil activation and the NET formation pathway, contributing to thrombus formation, and when these thrombi are washed ashore and attach to the pulmonary arteries, which are the end of systemic venous flows, the pathogenesis of CTEPH is generated. CH indicates clonal hematopoiesis; CTEPH, chronic thromboembolic pulmonary hypertension; NET, neutrophil extracellular trap; and RBC, red blood cell. In regard to the clinical impact of CH, the BNP value and HOT usage rate were significantly higher and 6MWD was significantly shorter after treatment in patients with CH than in those without CH. Also, improvement of BNP by treatment tended to be less in patients with CH than that in patients without CH. Moreover, the 2‐way repeated measure analysis of variance as another statistical method to assess the statistical difference of repeated measured values demonstrated the significant difference in BNP change between patients with and without CH. Although the change in 6MWD was not different between the patients with and without CH, a high number of missing values could affect the results. One possible explanation for the difference in the BNP value, HOT usage rate, and 6MWD after treatment is the higher incidence of novel thrombi in the pulmonary artery. Because only the obvious thrombi could be recognized by the pulmonary angiography and chest computed tomography scan, the micro clot could not be recognized. These thrombi could affect the pulmonary vascular bed, leading to a higher BNP value, higher HOT usage rate, and shorter 6MWD after treatment. Additionally, the possibility that the hemodynamics of patients with CH in this study may have been exacerbated during exercise could not be excluded, because it has been reported that patients with chronic thromboembolic pulmonary disease with exercise pulmonary hypertension have reduced exercise capacity even when their hemodynamics obtained using RHC at rest normalize. 33 Finally, the fact that the rate of additional BPA was higher and more events of novel thrombus in the pulmonary artery occurred in patients with CH implies that an appropriate management with anticoagulant therapy for patients with CTEPH having CH needs to be verified in the future studies. Patients with PH with hematological disorders are classified as group 5 PH, therefore patients with CTEPH with hematological disorders may be different from classical CTEPH. In the previous analysis, Eichstaedt et al demonstrated that the JAK2 V617F variant was found among patients with hematological disorders in 3 of 40 CTEPH cases. 34 Recently, the JAK2 V617F variant has been reported to be particularly at risk for hematological malignancy. 35 In the present analysis, the hematological disorders were identified in 11.6% of patients with CTEPH with CH, including 3 patients with ET who had the JAK2 V617F variant. Thus, it is implied that JAK2 V617F could be particularly relevant to the pathogenesis of CTEPH with hematological disorders. To eliminate the influence of the presence of hematological disorders associated with disease severity, a subgroup analysis in a cohort of patients without hematological disorders was also performed in this study. In the subgroup analysis, 18.4% of patients with CTEPH without hematological disorders had CH, and they showed poorer clinical response, more often a prothrombic state, and greater upregulation of NET formation pathway than patients without CH. These results suggest that CH itself could be a risk factor for poor clinical response and prothrombotic state in patients with CTEPH, although the presence of missing values might affect the result of clinical comparison between the CH‐positive group and CH‐negative group. This study had some limitations. First, although the CH frequency in patients with CTEPH was compared with the patients with cardiomyopathy, comparison with the cohort in the general population or patients with acute pulmonary embolism could not be performed. To investigate the contribution of CH to CTEPH pathogenesis, comparison with those cohorts would be warranted. Second, the confounders could not be sufficiently adjusted for despite multivariate analysis due to the low number of events, and the clinical comparisons in this study may have unadjusted confounders, because various factors, such as smoking, cancer therapy, unhealthy diet habits, chronic infection, and inflammatory diseases, could increase the risk of CH. 36 , 37 , 38 , 39 , 40 Third, the demonstration of variants in genes associated with CH is not equivalent to demonstration of CH. This is because we cannot rule out the possibility that unknown CH‐associated genes could be latent in patients with CTEPH, or that some of the CH‐associated genes were not detected in this study due to technical limitations. Finally, although this study showed the potential involvement of the NET formation pathway through CH in CTEPH using patients’ samples, the direct involvement of NETosis could not be assessed, and further molecular biological in vitro and in vivo studies are warranted. Furthermore, prospective validation for developing preventative measures and therapeutics focusing on CH and intervening in the NET formation pathway is necessary. In conclusion, we reported the high prevalence and clinical impact of CH in patients with CTEPH. The findings in this study raise the possibility that CH induces a more prothrombotic state through neutrophil activation and the NET formation pathway, contributing to CTEPH pathogenesis and poor treatment response. Sources of Funding This research was supported by the Japan Agency for Medical Research and Development under grant number JP23ek0109535. Disclosures None. Supporting information Tables S1–S13 Figures S1–S3 M. Momoi and Y. Katsumata contributed equally. This article was sent to Suha Bachir, MD, MS, Assistant Editor, for review by expert referees, editorial decision, and final disposition. Supplemental Material is available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.124.035498 For Sources of Funding and Disclosures, see page 12. References Associated Data Supplementary Materials Tables S1–S13 Figures S1–S3